Meridian Bioscience Inc.

NASDAQ:VIVO   3:59:51 PM EDT
32.58
+0.05 (+0.15%)
Earnings Announcements

Meridian Bioscience Inc Reports Q3 Net Loss Per Basic Common Share Of $0.17

Published: 08/05/2022 12:28 GMT
Meridian Bioscience Inc. (VIVO) - Meridian Bioscience Reports Third Quarter Fiscal 2022 Operating Results.
Q3 Revenue Rose 7 Percent to $67.8 Million.
at June 30, 2022, Cash and Cash Equivalents Were $83.5 Million.
Qtrly Net Loss per Basic Common Share $0.17.
Revenue is expected to be $67.45 Million
Adjusted EPS is expected to be $0.15

Next Quarter Revenue Guidance is expected to be $71.45 Million
Next Quarter EPS Guidance is expected to be $0.20

More details on our Analysts Page.